NCT02690545View on ClinicalTrials.gov

Study of CD30 CAR for Relapsed/Refractory CD30+ HL and CD30+ NHL

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

August 26, 2016

Primary Completion Date

September 10, 2027

Study Completion Date

August 26, 2038

Conditions
LymphomaLymphoma, Non-HodgkinImmune System DiseasesImmunoproliferative DisordersLymphatic DiseasesLymphoproliferative DisordersNeoplasmsNeoplasms by Histologic Type
Interventions
BIOLOGICAL

ATLCAR.CD30 cells

For Phase Ib, in adults and separately in children, two doses will be investigated: 1x10\^8 cells/m\^2 and 2x10\^8 cells/m\^2. Phase II patients will receive the dose level decided upon in Phase I.

Trial Locations (1)

27599

RECRUITING

Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill

All Listed Sponsors
lead

UNC Lineberger Comprehensive Cancer Center

OTHER